US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R01 – Clinical Trial Not Allowed)

This opportunity uses the R01 Research Project Grant funding mechanism.

Funding Opportunity Announcement (FOA) Number: PAR-18-830

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute and the National Eye Institute invite applications for their role of epitranscriptomics in development and disease (R01 clinical trial not allowed) funding opportunity.

This supports research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the participating institutes.

Companion Schemes

  • PAR-18-831, R21 Exploratory/Developmental Research Grant

Funding & Duration

The number of awards is contingent on NIH appropriations and the submission of a sufficient number of meritorious applications. Grants are worth up to USD $499,999 (approx. AUD $676,000) each, for a maximum period of five years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.